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The human 2-oxoglutaric acid dehydrogenase complex
(hOGDHc) plays a pivotal role in the tricarboxylic acid (TCA)
cycle, and its diminished activity is associatedwith neurodegen-
erative diseases. The hOGDHc comprises three components,
hE1o, hE2o, and hE3, and we recently reported functionally
active E1o and E2o components, enabling studies on their
assembly. No atomic-resolution structure for the hE2o compo-
nent is currently available, so here we first studied the interac-
tions in the binary subcomplexes (hE1o–hE2o, hE1o–hE3, and
hE2o–hE3) to gain insight into the strength of their interactions
and to identify the interaction loci in them. We carried out
multiple physico-chemical studies, including fluorescence,
hydrogen–deuterium exchange MS (HDX-MS), and chemical
cross-linkingMS (CL-MS).Our fluorescence studies suggested a
strong interaction for the hE1o–hE2o subcomplex, but a much
weaker interaction in the hE1o–hE3 subcomplex, and failed to
identify any interaction in the hE2o–hE3 subcomplex. The
HDX-MS studies gave evidence for interactions in the hE1o–
hE2o and hE1o–hE3 subcomplexes comprising full-length
components, identifying: (i) the N-terminal region of hE1o, in
particular the two peptides 18YVEEM22 and 27ENPKSVHK-
SWDIF39 as constituting the binding region responsible for the
assembly of the hE1o with both the hE2o and hE3 components
into hOGDHc, an hE1 region absent in available X-ray struc-
tures; and (ii) a novel hE2o region comprising residues from
both a linker region and from the catalytic domain as being a
critical region interacting with hE1o. The CL-MS identified the
loci in the hE1o and hE2o components interacting with each
other.
Thehuman2-oxoglutaratedehydrogenasecomplex(hOGDHc)4
is a key enzyme in the tricarboxylic acid (TCA) cycle. The
diminished physiological activity of the hOGDHc and oxida-
tive stress had been correlatedwithmultiple neurodegenerative
diseases, including Alzheimer’s disease and Parkinson’s disease
(1, 2); however, a link between diminishedOGDHc activity and
impaired glucose metabolism is not well established. At pres-
ent, hOGDHc is recognized as a significant source of the reac-
tive oxygen species (superoxide and H2O2) that could lead to
oxidative stress in mitochondria (3, 4). Another function sug-
gested for hOGDHc is that it could be involved in histonemod-
ifications by lysine succinylation that represents an important
mechanism for regulation of gene expression (5). Also, revers-
ible post-translational succinylation of the cytosolic and mito-
chondrial proteins by hOGDHc in neuronal cell lines and in
cultured neurons was suggested (1).
Recently, we have reported findings in vitro suggesting both
functional and regulatory cross-talk between the hOGDHc and
a novel human 2-oxoadipate dehydrogenase complex from the
final degradation pathway of L-lysine, L-hydroxylysine, and
L-tryptophan, demonstrating that the two complexes share the
same dihydrolipoyl succinyltransferase (hE2o) and dihydroli-
poyl dehydrogenase (hE3) components (7). These findings
raised important questions about assembly of the individual
components in these two complexes and regarding the physio-
logical relevance of such assemblies, informationwhich ismiss-
ing to date.
The hOGDHc is a macromolecular assembly comprising
multiple copies of three enzyme components, similar to other
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2-oxo acid dehydrogenase complexes, which display a remark-
able active-site couplingmechanism (8, 9). The thiamin diphos-
phate (ThDP)-dependent 2-oxoglutarate dehydrogenase com-
ponent (hE1o, EC 1.2.4.2) catalyzes the decarboxylation of
2-oxoglutarate, releasing CO2, followed by the reductive succi-
nylation of the dihydrolipoamide succinyltransferase compo-
nent (hE2o, EC 2.3.1.6), which has a single lipoyl domain, car-
rying a covalently amidated lipoic acid as a redox cofactor. The
reductive succinylation reaction of hE2o by hE1o is followed by
trans-thiol esterification of the succinyl group onto CoA in the
active centers of hE2o, generating succinyl-CoA. The dihydro-
lipoamide dehydrogenase component (hE3, EC 1.8.1.4), with a
tightly but noncovalently bound FAD as cofactor, re-oxidizes
dihydrolipoamidated hE2o to commence the next turnover,
while concomitantly reducing an equivalent of NAD to
NADH (10–17).
Historically, the oligomeric E2 component has been assumed
to be the core of the 2-oxo acid dehydrogenase multienzyme
complexes, to which multiple copies of the E1 and E3 compo-
nents (sometimes called peripheral components) are noncova-
lently attached (18–21). As to the OGDHc, both the human
E2o and the Escherichia coli E2o components have a single
N-terminal lipoyl domain (LDo) connected by a long linker to
the core domain (CDo) (22). An amino acid sequence align-
ment of the hE2o with known E2o components from bacterial
and mammalian sources has failed to identify any sequence
corresponding to a peripheral subunit-binding domain (PSBD)
for E1o and E3 binding (23–26) nor is there a fourth component
present corresponding to E3-binding protein (E3BP), an addi-
tional component found in the mammalian pyruvate dehydro-
genase complex (PDHc) (11, 27–31).
To date, there is no X-ray crystal structure for any of the
2-oxo acid dehydrogenase complexes in their intact state, pos-
sibly due to their size (Mr of 4–10 million) and flexible attach-
ment of the E1 and E3 components to the core (25, 32, 33). The
numbers and distribution of E1s and E3s around the core sur-
face also vary from complex to complex (34). X-ray structural
data have been published for truncated Escherichia coli E1o
lacking its N-terminal region but providing information about
the E1o active centers (35). However, no information about E1o
contacts with the E2o and E3 components was apparent in
this structure (35). Earlier, based on studies with mammalian
OGDHc subjected to tryptic digestion, it was suggested that the
N-terminal region of the mammalian E1o could form contacts
with the E2o and E3 components (36–38). Additionally, an
X-ray structure of the Mycobacterium smegmatis -ketogl-
utarate decarboxylase lacking 115 N-terminal amino acid resi-
dues had been reported (39), once more missing information
regarding the flexibleN-terminal region. Structural approaches
have been successfully applied to the E. coli E2o lipoyl domain
(40), to the E. coli E2o truncated cubic core (41), and to the
E. coli E3-binding domain of the E2o (42); however, no high-
resolution X-ray structures for any full-length E2o component
or E2o-core assembly are available at present.
These observations served as our hypothesis and motivation
to establish the loci and strength of interaction in the binary
hE1o–hE2o, hE1o–hE3, and hE2o–hE3 subcomplexes. Our
principal structural tool was H/D exchange MS (HDX-MS),
which the Rutgers’ group has already applied (among other
studies) to the following. (i) Elucidation of the interaction loci
of the human pyruvate dehydrogenase complex E2E3BP core
with the human pyruvate dehydrogenase kinases 1 and 2 (43).
(ii) An understanding of the structural alterations induced by
disease-causing mutations in the human E3 component (44).
Taken together, our data reported here suggest that both hE2o
and hE3 interact with the same peptides located at the N-ter-
minal region of hE1o, revealing that the N terminus of hE1o is
pivotal for mediating assembly of the entire hOGDHc and sug-
gesting a new mode of assembly in the superfamily of 2-oxo
acid dehydrogenase complexes.We complement the HDX-MS
studieswith chemical cross-linkingmass spectrometric studies.
These cross-linking mass spectrometric studies provide strong
evidence for which locus on hE1o interacts with which locus on
hE2o and are in agreement with all other results.
Results and discussion
Probing the interactions between the hE1o, hE2o, and hE3
components in binary subcomplexes
The ability to produce active, full-length hE1o, hE2o, and
hE3 components and to assemble them into functionally active
hOGDHc enabled us to evaluate the strength and loci of inter-
action in the binary hE1o–hE2o, hE1o–hE3, and hE2o–hE3
subcomplexes. Experiments using size-exclusion chromatogra-
phy (SEC) and isothermal titration calorimetry (ITC) revealed
formationof a binary hE1o–hE2o subcomplex (Fig. 1).Onmea-
suring heats of interaction of hE1o with hE2o, formation of the
binary subcomplex was found to be endothermic (positive
peaks in the ITC input, H  12.1 kcal/mol) and displayed
saturation with an estimated Kd of 0.95  0.10 M (Ka 
1.057  106 M1) for their binding (Fig. 1A). Binding was also
accompanied by a large positive entropy change (TS  20.6
kcal/mol). However, a lowN value of 0.1999 0.0069 was esti-
mated from the fit of the experimental data. The reduction inN
value is likely due to self-assembly of the hE2o subunits to form
a 24-meric cube core as in hOGDHc or even larger E2o assem-
blies. Thus, although the ITC experiment suggests strong inter-
action between the hE1o and hE2o, this method could not
provide an accurate assessment of the stoichiometry of their
binding.
Formation of the hE1o–hE2o subcomplex was also sug-
gested by a 1H-15NTROSY-HSQCNMRexperiment using uni-
formly 15N-labeled hE1o as shown in Fig. S1. The superimposed
1H-15N TROSY-HSQC spectra of 15N-labeled hEo in the
absence and in the presence of hE2o revealed multiple differ-
ences in the spectrum of 15N-labeled hE1o on interaction with
hE2o. While at this level of analysis (no sequence-specific
assignments were made on these large enzymes with mass of
	200,000 Da for the hE1o homodimer and hE2o oligomer of
	45,000 Da per subunit), these NMR results do not provide
information about the loci of interaction, but they do sup-
port the presence of interaction in the binary hE1o–hE2o
subcomplex.
In contrast, the hE3, which is shared by all members of the
2-oxo acid dehydrogenase complex family in amammalian cell,
forms unstable binary subcomplexes with hE1o and hE2o
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according to SEC experiments, where each protein in the pre-
formed binary hE1o–hE3 and hE2o–hE3 subcomplex was
eluted as an individual peak (Fig. S2). A similar conclusion
could also be drawn from ITC titration experiments where
hE1o or hE2o were titrated by hE3 (Fig. S3). The titration plots
did not exhibit saturation (Fig. S3),more probably due to aweak
and transient binding between components (34). According to
the accepted OGDHc mechanism, with each turnover, the
reduced lipoyl domain (dihydrolipoamide) on hE2o must be
re-oxidized by the FAD on hE3 (45, 46).
The exact stoichiometry of the assembly of the hE1o, hE2o,
and hE3 components into hOGDHc is unknown. Earlier it was
reported that the isolated E. coli E2o core (octahedral (24-mer))
could bind six E1o dimers (2) compared with the E. coli E2p
(octahedral (24-mer)) that could bind 12 E1p (2) dimers and
six E3 (2) dimers (14). On assembly of the hOGDHc from its
individual components followed by removal of the excess of
hE1o and hE3 by passing their mixture through the analytical
column, a molar ratio of the hE1o/hE2o/hE3 subunits of 10.2:
13.4:2.7 was estimated from three independent experiments.
This subunit composition corresponds to an association of 5.1
hE1o dimers, 4.5 hE2o trimers, and 1.4 hE3 dimers correspond-
ing to an approximate stoichiometry of 3(hE1o)2/3(hE2o)3/
1(hE3)2. These data suggest that each (hE2o)3 binds one
(hE1o)2, and this stoichiometry is unaffected by the hE3 com-
ponent (Fig. S4).
Strength of hE1o–hE2o interactions as quantified by
site-specifically introduced external fluorophores into
hE2o-derived proteins
To help identify the loci of interaction between the hE1o,
hE2o, and hE3 components of the hOGDHc, we created trun-
cated versions of the hE2o:hE2o(1–95) (lipoyl domain, LDo,
comprising the lipoyl domain and part of the linker region), the
hE2o(1–173) di-domain, comprising the LDo, the linker region
and part of the hE2o core domain, and the C-terminal
hE2o(144–386) core domain, consisting of the hE2o core
domain and part of the linker region (see Fig. 2 for domain
structure of the hE2o). Two approaches were developed to
introduce an external fluorophore site-specifically onto the
truncated versions of the hE2o. In the first approach, the lipo-
amide carrying hE2o proteins, the hE2o(1–95) lipoyl domain,
and the hE2o(1–173) di-domain were dansylated (Scheme S1).
The lipoamide in both proteins was first reduced to dihydroli-
poamide using TCEP, then it was labeled with a dansyl group
that had been tethered to the amino group of 4-aminophenyl
arsenoxide, resulting from a reaction of the trivalent arsenoxide
with the reduced dihydrolipoamide (Scheme S1) (47). In the
second approach, N-(1-pyrene) maleimide was used to label
the unique Cys37 in the hE2o(1–173) di-domain and Cys178 in
the hE2o(144–386) core domain. Titration of DANS-As–
labeled hE2o(1–95) lipoyl domain by hE1o resulted in quench-
Figure 1. Isothermal titration calorimetry and size-exclusion chromatography to probe the formation of the binary hE1o–hE2o subcomplex. A, ITC
probingof thehE1o–hE2o subcomplex formation. Toppanel, rawdataobtained froma series of 10-l injections of hE1o (25M subunit concentration) into the
cell containing hE2o (450M subunit concentration) and plotted as heat change versus time. Bottompanel: plot of the areas under peaks inA against themolar
ratio of hE1o injected. The Kd of 0.95  0.10 M for the hE1o–hE2o subcomplex formation was calculated from the fit of the experimental data to a single
site–binding model. B, SEC demonstration of the hE1o–hE2o binary subcomplex formation. The hE1o and hE2o were preincubated at 2:1 molar ratio of
subunits in 50 mM KH2PO4 (pH 7.5) containing 0.15 M NaCl, 0.5 mM ThDP, and 1.0 mM MgCl2 for 1 h at room temperature followed by elution on an analytical
Superose 6 columnwith 1ml/min flow rate (black). In control experiments, the hE1o by itself was elutedwith 14.4ml; the ThDP by itself was elutedwith 18–20
ml (both in green); the hE2o by itself was eluted in the void volume (brown). C, SDS-PAGE analysis of the eluted protein peaks (from B). Lanes 1–5 correspond to
hE1o–hE2o binary subcomplex, eluted with 6–11 ml. Lane 6 corresponds to hE1o by itself eluted with 14–16 ml.
Unique interactions between components of humanOGDHc
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ing of the fluorescence of dansylamide, as was also observed on
titration of DANS-As–labeled hE2o(1–173) di-domain, sug-
gesting that on interaction with hE1o, a more hydrophilic
microenvironment was created around the fluorophore (Fig. 3)
(48). The calculated Kd values were as follows: 0.135 M (with
hE2o(1–95) lipoyl domain) and 0.039 M (with hE2o(1–173)
di-domain), providing the first hint that the residues from the
linker region, which connects the lipoyl domain and the hE2o
catalytic domain and is present in the hE2o(1–173) di-domain,
could be an important determinant for the hE1o–hE2o
interaction.
With theN-(pyrene) maleimide-labeled hE2o(1–173) di-do-
main and hE2o(144–386) core domain proteins, on excitation
at 340 nm, three major fluorescence emission bands were in
evidence (374, 395, and 416 nm) (Fig. 4). The maximum emis-
sion intensities at 374 nm were used to calculate binding
parameters. In the spectrum of the hE2o(1–173) di-domain,
there was an additional broad peak centered around 470 nm,
which is likely due to excimer formation (Fig. 4) according to
the literature (49).
Addition of hE1o to the pyrene-labeled hE2o(1–173) di-do-
main quenched the pyrene fluorescence (Kd  0.041 M),
whereas addition of hE1o to the pyrene-labeled hE2o(144–386)
core domain enhanced the pyrene fluorescence intensity (Kd
0.06M), without any blue or red shift of the peak position (Fig.
3). The results suggested that interactions of hE1o with
hE2o(1–173) di-domain or with the hE2o(144–386) core
domain induce different changes in the microenvironment
around the pyrene fluorophore; interaction between hE1o and
labeled hE2o(1–173) leads the pyrene fluorophore to a rela-
tively more hydrophilic environment, whereas interaction of
hE1owith labeled hE2o(144–386) leads the pyrene fluorophore
to a more hydrophobic environment. The calculated Kd values
are in good accord when the interaction with the same protein
is measured with the two different fluorophores (Fig. 3). The
fluorescence binding experiments enabled us to conclude that
the linker region in hE2o located between the lipoyl domain and
hE2o catalytic domain participates in the interaction with
hE1o.
Deuterium uptake changes detected by HDX-MS in hE1o on
interaction with hE2o and its truncated proteins
As a first step, HDX-MS experiments were conducted with
full-length hE1o and hE2o components. On-line digestion by
pepsin, followed by LC-MS analysis, resulted in 99 peptides for
hE1o (Table S1) and 19 peptides for hE2o (Table S2), many of
them partially overlapping, providing 94% sequence coverage
for hE1o and 66.8% sequence coverage for hE2o. The high-
sequence coverage on hE1o, including the N-terminal flexible
region corresponding to residues 1–77, whichwasmissing (res-
idues 1–77 removed by proteolysis) from the previous crystal-
lographic study of the E. coli E1o (35), enabled us to study the
structural changes on assembly of the binary subcomplexes. On
digestion of hE2o with pepsin, almost 100% sequence coverage
resulted for its core domain, corresponding to residues 144–
386. However, the information about many peptides from the
lipoyl domain and linker region was missing due to being rela-
tively sparse in hydrophobic residues, proline residues (total of
26 prolines in these two regions), and charged residues, leading
to poor digestion by pepsin. Because of all the above consider-
ations, we also examined interaction of hE1o with the hE2o(1–
173) di-domain and the hE2o(144–386) core domain.
A summary of the HDX-MS analysis of the peptic peptides
originating from hE1o in the absence and in the presence of
hE2o is provided in Fig. 5. Below, we focus the discussion on
that subset of hE1o peptides, which displayed statistically sig-
nificant difference in deuterium uptake upon interaction with
hE2o. The major findings on hE1o are as follows.
(i) TheHDX-MS experiments indicate that the interaction of
hE1o with hE2o did not induce large-scale conformational
changes in hE1o (Fig. 5B). However, local backbone amide pro-
ton perturbations were indeed observed.
(ii) Importantly, two regions from the N-terminal end of
hE1o comprising residues 18YVEEM22 and 27LENPKSVHK-
SWDIF40 were the unique regions, which experienced signifi-
cant deuterium uptake retardation on interaction with full-
length hE2o (Fig. 5), and also on interaction with the hE2o
(1–173) di-domain and hE2o(144–386) core domain at all
Figure2.Domainstructureof thehE2o.The followingE2o-derivedproteins
were created: hE2o(1–95) (lipoyl domain, LDo, encompassing the lipoyl
domain and the linker region partially); hE2o(1–173) di-domain, encompass-
ing the LDo, the linker region and the core domain partially; and hE2o(144–
386), hE2o core domain (CDo, encompassing the core domain and the linker
region partially). The hE2o(1–173) di-domain and hE2o(144–386) core
domain have 30-amino acid overlapping sequence.
Figure 3. Fluorescence titration curves for DANS-As–labeled. The
hE2o(1–95) lipoyl domain andhE2o(1–173) di-domain and for pyrene labeled
hE2o(1–173) di-domain and hE2o(144–386) core domains by hE1o are
shown. In all cases, the fluorescence intensity of the fluorophore-labeled
hE2o-derived protein was quenched on titration by hE1o. In a typical experi-
ment, the fluorophore-labeled hE2o-derived protein (1.0–2.0 M concentra-
tion of subunits) in 30mM KH2PO4 (pH 7.5) was titrated by hE1o (0.01–1.5M)
at room temperature. The excitation wavelength was 338 nm for DANS and
340 nm for pyrene labeled hE2o-derived proteins. The fluorescence titration
curves were fitted by using the Hill equation (Equation 5). Inset: calculated Kd
values are presented.
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exchange time points analyzed (Fig. 6). Thus, the hE1o peptides
comprising residues 18YVEEM22 and 27LENPKSVHKSWDIF40
represent the most likely candidates for binding with hE2o.
(iii) The HDX-MS results, together with the predicted second-
ary structure of theN-terminal region of hE1o presented in Fig. 7,
suggested that upon binding of the hE2o to hE1o, the two pre-
dicted helical N-terminal regions of hE1o consisting of residues
18YVEEM22 and 27LENPKSVHKSWDIF40 became less flexible.
(iv) In addition to the N-terminal region of hE1o, some
peptides near the putative ThDP- and Mg2-binding sites dis-
played modestly increased deuterium uptake (peptide consist-
ing of residues 407IGFTTDPRM415 and two peptides encom-
passing residues 529EAFARSKDEKILHIKHWLDSPWPGF553
and 554FTLDGQPRSMSCPSTGLTE572). The magnitude of
these small perturbations could be related to perturbations in
the hE1o catalytic center in response to hE2o binding. These
results lead us to a major conclusion that two N-terminal
regions of hE1o comprising residues 18YVEEM22 and 27LEN-
PKSVHKSWDIF40 are, most likely, candidates for binding with
hE2o.
Deuterium uptake changes identified in hE2o by HDX-MS on
interaction with hE1o
The Butterfly plot of the peptic peptides originating from
hE2o by itself and in the presence of hE1o (Fig. 8) revealed that
there were no major changes in deuterium uptake upon hE1o
binding. The lipoyl domain was too rigid to be digested by pep-
sin, resulting in low peptide coverage as was mentioned above.
Also, the hE2o region comprising residues from the linker
region and from the beginning of the core domain were not
covered due to a lack of pepsin cleavage in these regions. The
Butterfly plot also revealed that the following regions in the
hE2o core domain were highly protected even in the absence of
hE1o: 181LTTFNE186, 217FVKASAF223, and 369LRKIKAAVED-
PRVLL383, all three ofwhichhad almost nodeuteriumuptake at
all times of exchange used (Table S2 and Fig. 8B).
In view of the above uncertainties, we also carried out exper-
iments with the hE2o(1–173) di-domain and hE2o(144–386)
core domain, which provided complementary coverage of the
linker region (Tables S3 and S4). Upon binding of the hE2o
(1–173) di-domain to hE1o, the peptide encompassing resi-
dues 134AVKPTVAPPLAEAGAGKGLRSEHREKMNRMRQRI-
AQRLK172mostly from the hE2o linker region, and also includ-
ing the N-terminal region of the core domain, revealed a
significant decrease in deuterium uptake during the first 3 min
of the exchange time (Fig. 9A). However, this deuterium uptake
retardation quickly faded at a longer exchange time indicating a
weaker protection by hE1o at a longer time scale. The data
suggest involvement of the hE2o stretch of residues 134AVKPT-
VAPPLAEAGAGKGLRSEHREKMNRMRQRIAQRLK172 in its
interaction with hE1o. In a complementary experiment, it was
shown that upon binding of hE2o(144–386) core domain to
hE1o, the N-terminal peptide comprising residues 144AEAG-
AGKGLRSEHREKMNRMRQRIAQRLKEAQNTCAM180 from
the linker region and including the first 33 N-terminal residues
of the hE2o(144–386) core domain also displayed a significant
decrease in deuteriumuptake. The peptide comprising residues
134–172 in hE2o(1–173) di-domain and the peptide compris-
ing the first 33 residues in the hE2o(144–386) core domain
overlap significantly, having 30 amino acids in common, corre-
sponding to the following residues: 144AEAGAGKGLRSEH-
REKMNRMRQRIAQRLKE173. Because this is the only hE2o
region that displayed a significant decrease in the level of the
deuterium uptake upon hE1o binding, this region could be crit-
ical for the hE1o–hE2o interaction. A sequence alignment of
this 30-amino acid–long region with some known peripheral
subunit-binding domains in E2 components (Fig. 9B) allowed
us to identify conserved residues, suggesting that hE2o shares
some but not all sequence features of other subunit-binding
domains that are believed to be important for E1o binding. This
experiment allowed us to conclude that in contrast to other E2s,
Figure 4. Fluorescence titration of pyrene-labeled hE2o(1–173) di-domain andpyrene-labeled hE2o(144–386) core domain by hE1o. A, quenching of
the fluorescence of pyrene-labeled hE2o(1–173) di-domain by hE1o. Pyrene-labeled hE2o(1–173) di-domain (1.5M active centers) in 30mM KH2PO4 (pH 7.5)
was titrated by hE1o (0.013–0.261 M). B, enhancement of the fluorescence of the pyrene-labeled hE2o(144–386) core domain on hE1o binding. Pyrene-
labeled hE2o(144–386) core domain (1.5 M) in 30 mM KH2PO4 (pH 7.5) was titrated by hE1o (0.013–0.261 M).
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Figure 5. ComparativeHDX-MS analysis of the hE1o by itself and of the hE1o on interactionwith hE2o. A, Butterfly plot representing relative deuterium
incorporation percentage (D%, y axis), deuterons exchanged/maximum exchangeable amides  100% of peptic peptides from E1o (x axis, listed peptic
peptides from the N to C terminus) in the absence of hE2o (right) versus in the presence of hE2o (left) based on three independent experiments. B, difference
plot showing the changes in deuterium incorporation of peptic fragments of hE1o in the absence and presence of hE2o (D, y axis), (deuterons exchanged
in the absence and presence of hE2o).
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the binding region of hE2o is extended to its core domain with
corresponding residues (157REKMNRMRQRIAQRLKE173)
that represent a unique hE2o-binding mode in the human
OGDHc (remark: the residues are not unique but the hE2o-
binding mode is unique). The observation that the linker-core
region of hE2o is the critical region interacting with hE1o does
raise the possibility that this region on hE2omight also serve as
a binding site for the hE3 component.
HDX-MS identification of the binding loci in the E1o–E3 and
E2o–E3 binary subcomplexes
Digestion of hE3 by pepsin followed by LC-MS analysis
resulted in 27 peptides, with some of them partially overlap-
ping, and provided 90.9% sequence coverage (Table S5). Upon
binding of hE1o to hE3, many regions on both hE1o and hE3
were observed to undergo changes in deuterium uptake (Figs.
S5 and S6). (i) On the hE1o, significant changes were identified
in the N-terminal region and in the ThDP-binding fold (Fig.
S5). In particular, peptides encompassing residues 18YVEEM22,
27LENPKSVHKSWDIF40, and 119DSSVPADIISSTDKLGF135
from the N-terminal region of hE1o and peptides encompassing
residues 299EAADEGSGDVKYHLGM314, 315YHRRIN-
RVTDRNIT328, 505LVSQGVVNQPEYEEE519, 529EAFARSK-
DEKILHIKHWLDSPWPGF553, and 554FTLDGQPRSMSC-
PSTGLTE572 from the ThDP-binding fold of hE1o displayed a
decrease in deuteriumuptake during the first 3min of exchange
(Fig. S5). Notably, the two peptides with residues 18YVEEM22
and 27LENPKSVHKSWDIF40 from the N-terminal region of
hE1o displayed the most significant decrease in deuterium
uptake while associated with hE3. These two peptides were
also found to be significantly protected in the hE1o–hE2o
subcomplex (Fig. 5). This finding, together with the fact that
the N-terminal region of hE1o showed limited similarity
to the corresponding sequence in the hPDHc E3-binding
protein, suggested that the N-terminal region of hE1o, in
particular the two peptides 18YVEEM22 and 27ENPKSVHK-
Figure 6. A, deuterium uptake difference plot for peptide encompassing residues 18–22 in hE1o on interaction with hE2o, hE2o(1–173) di-domain, and
hE2o(144–386) core domain. B, deuterium uptake difference plot for peptide encompassing residues 27–40 in hE1o on interaction with hE2o, hE2o(1–173)
di-domain, and hE2o(144–386) core domain.
Figure7.Predictedsecondary structure for theN-terminal regionof thehE1oencompassing residues1–152.Thecalculationswereperformedusing the
JPred program (http://www.compbio.dundee.ac.uk/jpred/) (65, 66). (Please note that the JBC is not responsible for the long-term archiving andmaintenance
of this site or any other third party hosted site.) The highlighted two-helices (in red) were found to have significant decreases in the level of deuteriumuptake
when hE1owas incubatedwith hE2o. The tertiary structure predictionwas performed using I-TASSER and SWISS-MODEL (http://swissmodel.expasy.org/) was
employed.
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SWDIF39, constitute the binding region responsible for the
assembly of the hE1o with both the hE2o and hE3 compo-
nents into hOGDHc.
On the hE3 partner, upon binding to hE1o, two peptides
encompassing residues 35EKNETLGGTCLNVGCIPSKALL-
NNSHYYHMAHGKD69 and 107FKQNKVVHVNGYGKITG-
KNQVTATKADGGTQVIDTKNIL145 in the FAD-binding
domain of hE3, and one peptide 381YKVGKFPFAANSRAKT-
NADTDGM403 from the interface domain of hE3, showed the
most significant decrease in deuterium uptake (Fig. S6). This
result is consistent with our data reported recently (43) where
the same hE3 peptides showed a decrease in deuterium uptake
on interaction with the hE3-binding domain of the human
PDHc, indicating a similar binding mode in both.
In contrast to the evidence for the hE1o–hE3 interaction, the
HDX-MS data did not provide clear evidence for direct binding
between hE2o and hE3. Even though during the catalytic cycle
of hOGDHc, the reduced lipoic acid covalently attached to
hE2o must be re-oxidized by FAD on hE3, this transient inter-
action could be too weak to be captured by the method used
here, suggesting that the presence of hE1o is needed for assem-
bly of hE3 into hOGDHc.
Figure 8. Comparative HDX-MS analysis of the hE2o by itself and in the presence of hE1o. Top panel, Butterfly plot representing average relative
deuterium incorporation percentage (D%, y axis) (deuterons exchanged/maximumexchangeable amides 100%) of peptic peptides from the hE2o, (x axis,
listed peptic peptides from the N to C terminus)) in the absence of hE1o (top part) versus in the presence of hE1o (bottom part). Bottom panel, difference plot
showing the change in deuterium incorporation of peptic fragments originated from hE2o in the absence and presence of hE1o (D, y axis) (deuterons
exchanged in the absence minus deuterons exchanged in the presence of hE1o).
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Chemical cross-linking of hE1o and hE2o
The HDX-MS studies above provide strong evidence for the
loci of inter-component interactions on both the hE1o and
hE2o components at a peptide resolution. But, when multiple
interaction loci are identified on each component, as is the case
here, the analysis needs to be taken to the next higher level, i.e.
which site on hE1o interacts with which site on hE2o? To
address this question, we carried out chemical cross-linking
analysis of full-length hE1o and hE2o components by using two
cross-linkers to react with the -amino side chain of the lysine
residues: 1,1-carbonyldiimidazole (CDI, C–C distance
16
Å to be bridged) (50) and urea-based disuccinimidyl dibutyric
urea (DSBU or BuUrBu, C–C distance
27 Å to be bridged)
(51). These two cross-linkers have an advantage of being
cleaved under mass spectrometric conditions. The covalent
adducts were analyzed byMS.We identified 160 and 23 unique
cross-linked residue pairs (cross-links) with CDI and BuUrBu,
respectively, at p 0.01. The majority of cross-links identified
are intra-component cross-links, i.e. two lysines from the same
component are being cross-linked. Of the several inter-compo-
nent cross-linked peptides (60 cross-linked residue pairs), we
selected the ones with p 0.001 (Table 1). The following cross-
links were identified.
On hE1o, the cross-linked Lys31 is located in the N-terminal
region, and the other cross-linked lysines are located on the
hE1o surface near the putative ThDP- and Mg2-binding sites
(see Table 1 and Fig. 10 for cross-linked lysines mapped onto
the hE1o structure). Importantly, the cross-link between hE1o
Lys31 and hE2o Lys85 from the linker region was identified by
both CDI and BuUrBu providing complementary information
on similar hE1o–hE2o interaction. As identified by HDX-MS
above, Lys31 is located on a unique peptide comprising residues
27LENPKSVHKSWDIF40 in hE1o that experienced significant
deuterium uptake retardation on interaction with the full-
length hE2o and also on interaction with the hE2o(1–173) di-
domain and the hE2o(144–386) core domain (see Fig. 10). A
film (see Fig. S7 a film in mpg) clearly indicates that the hE1o
lysines participating in the cross-links are all on the surface.
On hE2o, the cross-linked lysines identified were as follows:
Lys78 from the lipoyl domain; Lys150 from the linker region; and
Lys172, Lys289, and Lys371 from the hE2o core domain. The
Lys172 is part of the hE2o(1–173) di-domain that displayed

3.5-fold weaker binding constant for hE1o compared with
lipoyl domain by itself. Importantly, the hE2o region compris-
ing residues 144AEAGAGKGLRSEHREKMNRMRQRIAQR-
LKE173 from the linker region (residues 144–156) and from
Figure 9. A, deuterium uptake difference plot for peptide encompassing residues 134–172 in hE2o on interaction with hE1o. B, sequence alignment of the
human hE2o linker-core regionwith sequences of the known peripheral subunit-binding domains. The abbreviations are denoted: human (h), Escherichia coli
(Ec), Bacillus stearothermophilus (Bst), Pseudomonas putida (Pp), and Azotobacter vinelandii (Av), 2-oxoglutarate dehydrogenase complex (o), pyruvate dehy-
drogenase complex (p), andbranched chain 2-oxoacid dehydrogenase complex (b). Alignment ofmultiple sequenceswas carried out using theClustal Omega
program (http://www.ebi.ac.uk/Tools/msa/clustalo/) (64) with default settings. (Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.)
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the core domain (residues 157–173) displayed a significant
decrease in deuterium uptake upon hE1o binding. The cross-
linking experiments provide strong support for the involve-
ment of the hE2o core domain in the hE1o–hE2o subcomplex,
not realized previously for any of the E1–E2 subcomplexes.
Conclusions
1) Strong interactions were identified between the hE1o- and
hE2o-derived truncated proteins. The fluorescence experi-
ments using the hE2o(1–173) di-domain and hE2o(144–386)
core domain, which revealed strong interactions with hE1o (Kd
in the 0.04–0.14M range), implied that the hE2o linker region
connecting the hE2o lipoyl domain and hE2o core domain is
involved in the interaction with hE1o.
2) In the hE1o–hE2o binary subcomplex, two peptides from
theN-terminal region of hE1o comprising residues 18YVEEM22
and 27LENPKSVHKSWDIF40 were identified, which experi-
enced significant deuterium uptake retardation on complex-
ation with hE2o and its derived hE2o(1–173) di-domain and
hE2o(144–386) core domain proteins. Therefore, these two
hE1o peptides represent the most likely candidates for binding
with hE2o.
3) On hE2o, the region comprising residues from the core
domain (in bold) and linker region (AEAGAGKGLRSEH-
REKMNRMRQRIAQRLKE) displayed a significant decrease
in the level of deuterium uptake upon complexation with hE1o,
and this could be critical for the hE1o–hE2o interaction. In
contrast to other E2s, part of the hE2o core domain also partic-
ipates in the interaction with hE1o, suggesting a unique sub-
unit-binding mode in human OGDHc assembly.
4) For the hE1o–hE3 binary subcomplex, only weak interac-
tions could be observed. According to HDX-MS, similarly to
the finding with the hE1o–hE2o subcomplex, two peptides
spanning residues 18YVEEM22 and 27LENPKSVHKSWDIF40
from the N-terminal region of hE1o displayed the most signif-
icant decrease in deuterium uptake upon assembly with hE3.
On the hE3 partner, two peptides comprising residues 35–70
and 107–145 from the FAD-binding domain and one peptide
comprising residues 381–403 from the interface domain of hE3
displayed a decrease in deuteriumuptake on complexationwith
hE1o.
5) The HDX-MS data failed to provide convincing evidence
for direct interaction between hE2o and hE3 in the absence of
hE1o. In view of the obligatory interaction of the dihydrolipoyl
domain of hE2o with the FAD-binding site of hE3, this result
suggests a weak and short-lived interaction.
6) Given the fact that the N-terminal region of hE1o displays
only limited similarity to corresponding sequences in the
E3-binding protein, residues 18–40 in hE1o may constitute a
unique dual-subunit–binding domain (DSBD) in hOGDHc.
Similar to the PSBD in the bacterial E2 enzymes, in the
hOGDHc assembly both the hE2o and hE3 components bind to
hE1o via this novel DSBD. It is worth noting that the dimeric
hE1o component could bind hE2o and hE3 simultaneously.
7) Finally, two cross-linking agents were used to identify the
following. (a) The most prominent loci on hE1o interacting
with hE2o was indeed the N-terminal region once more, and
the thiamin diphosphate environments were identified. (b) On
hE2o, the lipoyl domain and the linker-core region were found
to participate in cross-links with hE1o. These two powerful
mass spectrometric methods provided complementary results
in excellent agreement with each other.
In summary, this study identified unique sites for inter-com-
ponent interactions in this important human TCA enzyme
complex. On the hE1o component, the N-terminal region was
identified as a binding locus for both hE2o and hE3. An initial
formation of the uniquely strong hE1o–hE2o interaction facil-
itates assembly with hE3 to form the humanOGDHc assembly.
Figure 10. Homology modeling of the hE1o dimer structure with lysine
residues involved in inter-component cross-linking highlighted in pur-
ple. The structure of the hE1o dimer was modeled based on amino acid
sequence homology with the E. coli E1o (PDB code 2JGD (35)) and M. smeg-
matis E1o (PDB code 2YIC (39)) whose X-ray structures are available. The hE1o
homodimer is colored in yellow and green. The identified inter-component
cross-linked lysine residues (Lys297, Lys309, Lys362, Lys495, Lys627, and Lys868)
are highlighted in purple and were positioned by sequence alignment of the
hE1o with E. coli E1o. The identified lysine residues and ThDP cofactors are
shownas space-filling representations. TheprogramRIBBONS (6)was used to
create this figure.
Table 1
Inter-component cross-linksbetween thehE1oandhE2o components
identified by LC-MS-MS for the CDI and BuUrBu cross-linkers
a CDI is 1,1-carbonyldiimidazole (C–C distance
16 Å to be bridged).
b BuUrBu is disuccinimidyl dibutyric urea (C–C distance
27 Å to be bridged).
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Experimental procedures
Materials
The materials and sources used in this study are as follows.
ThDP, DL--lipoic acid, IPTG, thiaminHCl, imidazole, and iso-
propyl 1-thio--D-galactopyranoside (IPTG) were purchased
from Affymetrix. DNase, micrococcal nuclease, and E. coli
BL21(DE3) were purchased fromNew England Biolabs. Deute-
rium oxide (D2O) and 15NH4Cl (99%) were from Cambridge
Isotope Laboratories. Dansyl chloride, p-arsanilic acid, benz-
amidine hydrochloride hydrate, and 2,6-dichlorophenolindo-
phenol sodium salt hydrate were from Sigma. N-(1-Pyrene)
maleimide was purchased from AnaSpec, Inc. KOH, HEPES,
KCl, MgCl2, and phenylmethylsulfonyl fluoride (PMSF) were
from ThermoFisher Scientific. Nickel-Sepharose 6 Fast flow
was from GE Healthcare.
Construction of plasmids for expression of C-terminally
truncated hE2o proteins
ThepET-15b-hE2oplasmid encoding theHis6 tag hE2o from
the N-terminal end was used as a template, and the amplifica-
tion primers and their complements were used for site-directed
mutagenesis to introduce a TAA stop codon in place of Lys88,
Glu174, and Gln176 (the numbers includeMet as the first amino
acid). The following C-terminally truncated hE2o proteins
were created: hE2o(1–87), so-called lipoyl domain comprising
the lipoyl domain (residues 1–77) and part of the linker region
(residues 78–87); hE2o(1–173) di-domain comprising the LDo
and part of the linker region. The C-terminally truncated hE2o
proteins were expressed in BL21 (DE3) cells (New England Bio-
labs) in LB medium supplemented with ampicillin (50 g/ml)
and 0.3 mM DL--lipoic acid (Affymetrix). Protein expression
was induced by 0.5 mM IPTG at 30 °C for 15 h. Cells were col-
lected and were stored at20 °C.
Construction of plasmid for expression of N-terminally
truncated hE2o(144–386) core domain
The gene encoding C-terminally His6-tagged hE2o(144–
386) core domain was synthesized by ATUM (Newark, CA).
The gene was optimized for expression in E. coli cells and was
inserted into the pET-22b() vector through the NdeI and
XhoI restriction sites, and the resulting plasmid was expressed
in BL21(DE3) cells. Protein expression was induced by 0.5 mM
IPTG for 15 h at 18 °C. The harvested cells were stored at
20 °C.
Expression and purification of hE1o, hE2o, and hE3
components
Expression and purification of hE1o and hE3 was as
reported earlier (52). Purification of hE2o was carried out as
reported by us earlier for purification of the human
E2pE3BP core (43).
Purification of C- and N-terminally truncated hE2o proteins
Purification of C- and N-terminally truncated hE2o proteins
was as reported by us earlier for the E. coli E2o di-domain (53,
54). Cells were dissolved in 50mMKH2PO4 (pH 7.5) containing
1 mM benzamidineHCl, 1 mM PMSF, 0.30 M NaCl, and 20 mM
imidazole. Lysozyme was added to a final concentration of 0.60
mg/ml, and cells were incubated for 20 min at 4 °C. Next, 1000
units of DNase I (New England Biolabs) and micrococcal
nuclease (New England Biolabs) were added, and the cells were
incubated for an additional 40–60 min at 4 °C. Cells were then
disrupted using a sonic dismembrator. For more complete
removal of nucleic acids, the clarified lysate was additionally
treated by streptomycin sulfate (0.8% w/w final concentration)
for 20 min at 4 °C. The clarified lysate was applied to the Ni-
Sepharose 6 Fast Flow column equilibrated with 50 mM
KH2PO4 (pH 7.5) containing 0.3 M NaCl (buffer A) and 20 mM
imidazole. The column was washed with 700 ml of buffer A
containing 20 mM imidazole and then with 300 ml of buffer A
containing 35mM imidazole.Theproteinwas elutedwith300mM
imidazole in buffer A. Next, the protein was dialyzed against 50
mM KH2PO4 (pH 7.5) containing 0.5 mM EDTA, 1 mM
benzamidineHCl, and 0.3 M NaCl for 15 h at 4 °C, followed by
protein concentration using a concentrating unit with 10,000
MWCO, and finally the buffer was exchanged to 50 mM KH2PO4
(pH 7.5) containing 0.5 mM EDTA, 1 mM benzamidineHCl, and
0.15 MNaCl. Proteins were stored at80 °C.
Labeling of the lipoyl domain with DANS-As
The in vitro lipoylated LDo (50 M concentration, mass of
11,257.70 Da) in 30 mM KH2PO4 (pH 7.5) containing 0.15 M
NaCl was incubated with 100 M TCEP for 5 min at room
temperature, resulting in fully reduced LDo according to
FT-MS(massof thereducedLDo11,259.72Da),whichwas then
reacted with 150 M DANS-As for 2 h at room temperature to
form chemically modified LDo. The excess of TCEP and
DANS-As was removed using a centrifugal filter unit (Vivas-
pin 500, 10,000 MWCO). The DANS-As-labeled LDo was
diluted to 1 M with the ESI buffer (50:50:0.1 v/v/v mixture
of methanol, water, and formic acid) and was analyzed by
FT-MS in the positive ion mode as reported by our group
earlier (47). The mass of the DANS-As labeled LDo was esti-
mated to be 11,658.76 Da, in good accord with the expected
theoretical mass of 11,646.2 Da.
Labeling of the hE2o(1–173) di-domain and hE2o(144–386)
core domain with N-(1-pyrene)maleimide
The hE2o(1–173) di-domain and hE2o(144–386) core
domain (50 M), each containing a single cysteine residue at
positions 38 and 179, respectively, were incubated with 100 M
TCEP in 30 mM KH2PO4 (pH 7.5) containing 0.15 M NaCl for 5
min at room temperature. Then, 100MN-(1-pyrene)maleim-
idewas added, and the reactionmixturewas incubated for 2 h at
room temperature. The excess of TCEP and N-(1-pyrene)
maleimide were removed from the reaction mixture using a
centrifugal filter unit (Vivaspin 500, 10,000 MWCO). The pro-
tein labeling was confirmed by LC-MS. The labeled proteins
were first digested with trypsin. The LC-MS was carried out to
identify the peptides derivatized with the fluorophore. The
pyrene-labeled peptide originated from the hE2o(144–386)
core domain (EAQNTCAMLTTFNEIDMSNIQEMR), and the
mass of 3090.32 Da was identified in accord with the expected
theoretical mass of 3090.32 Da. Themass of the pyrene-labeled
peptide (AVGDTVAEDEVVCEIETDK) from the hE2o(1–173)
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di-domain with a mass of 2510.06 Da was also in good accord
with the theoretical mass of 2510.05 Da.
Preparation of the 15N-labeled hE1o for NMR studies
A single colony from the plate was inoculated into 20 ml of
the LB medium supplemented with 50 g/ml ampicillin, and
the cells were grown at 37 °C overnight. Cells were collected by
centrifugation, dissolved in 20 ml of the minimal medium sup-
plemented with 15NH4Cl (1.0 g/liter), and inoculated into 800
ml of the minimal medium supplemented with 15NH4Cl (1.0
g/liter). Cells were grown to an A600 of 0.5–0.6 at 37 °C, and
then the temperature was lowered to 20 °C, and the protein
expression was induced by the addition of 0.50 mM IPTG. Cells
were grown for 16 h. The 15N-labeled hE1owas purified using a
Ni-Sepharose 6 Fast Flow column with 10–300 mM imidazole
gradient in 50 mM K2HPO4 (pH 7.5) containing 500 mM NaCl,
0.5mMThDP, and 1.0mMMgCl2. The purified 15N-labeled E1o
was stored at80 °C.
Size-exclusion chromatography
SEC was performed using a Varian ProStar HPLC system
with a UV detector. A Yarra 3 SEC-3000 column with a
20-l sample loop was used at a flow rate of 1 ml/min. The
column was equilibrated with 50 mM KH2PO4 (pH 7.5) con-
taining 0.15 M NaCl, 0.5 mM ThDP, 1 mM MgCl2 and was
calibrated with the following protein standards (mass in Da
in parentheses): thyroglobulin (669,000), ferritin (440,000),
catalase (232,000), aldolase (158,000), BSA (67,000), and
ovalbumin (43,000). The elution of proteins from the col-
umn was at a flow rate of 1 ml/min and was monitored at 280
nm. The hE1o, hE2o (or hE2o truncated proteins), and hE3
were pre-incubated at various molar ratios for 1 h at room
temperature. Samples were centrifuged at 17,500  g for 5
min to remove any precipitated contaminations and were
applied to the column.
Isothermal titration calorimetry
ITC measurements were performed using a VP-ITC micro-
calorimeter (MicroCal, Northampton, MA). Titration experi-
ments were carried out in 50 mM KH2PO4 (pH 7.5), containing
100 mM KCl, 0.5 mM ThDP, and 2 mM MgCl2 at 15 °C. The
proteins were dialyzed for 15 h against the above buffer prior to
the experiment. For conditions of experiments, see the follow-
ing: legend to Fig. 1 for the hE1o–hE2o interaction and Fig. S3
for the hE3–hE1o and hE3–hE2o interactions. In a typical
experiment, the hE1o at 25–30 M concentration was titrated
by hE2o (or hE2o truncated proteins) or hE3 at 300–450 M
concentration. A single-site binding model was used for curve
fitting, and the binding constant (1.0/Kd) was calculated using
Origin version 7.0 software.
Fluorescence spectroscopy studies
All fluorescence spectra were recorded using a Varian Cary
Eclipse fluorescence spectrophotometer. The titration experi-
ments were conducted in 30 mM KH2PO4 (pH 7.5), containing
0.15 M NaCl.
For quenching the fluorescence of DANS-As–labeled
hE2o(1–95) lipoyl domain, hE2o(1–173) di-domain, and hE2o
(144–386) core domain by hE1o, the DANS-As–labeled hE2o
protein (1–2 M concentration of subunits) in 30 mM KH2PO4
(pH 7.5) was titrated by hE1o (0.05–1.05 M) at room temper-
ature. The excitation wavelength was 338 nm, and the emission
spectra were recorded in the 400–650 nm range. To calculate
Kd values, the fluorescence titration curves were fitted by using
Hill Equation 1.
F/Fmax E1O
n/Kd
n E1O
n (Eq. 1)
whereF/Fmax is relative fluorescence;F Fmax Fi, where
Fmax is a maximum fluorescence intensity reached on titration
by hE1o; and Fi is fluorescence intensity at a given concentra-
tion of hE1o; Fmax Fmax Fo, where Fo is the initial fluores-
cence before addition of hE1o;Kd, is the concentration of E1o at
half-saturation; n is the Hill coefficient.
For the quenching of the fluorescence of N-(1-pyrene)
maleimide-labeled hE2o(1–173) di-domain and hE2o(144–
386) core domain by E1o, the experimental conditions were
similar to those reported above for DANS-As-labeled hE2o-
truncated proteins. An hE1o concentration in the 0.01–0.80
M range was used for the titration. The excitation wavelength
was 340 nm, and emission spectra were recorded in the 350–
600 nm range. The maximum emission intensities at 374 nm
were used to calculate binding parameters according to Hill
Equation 1.
Hydrogen/deuterium exchangeMS
HDX-MS analysis was conducted as described by us earlier
using a 7TBrukerDaltonics FT-MS instrument (43, 44, 53–56).
The hE1o, hE2o, hE3, hE2o(1–173) di-domain, and hE2o
(144–386) core domain were analyzed individually and in their
binary subcomplexes. For sample preparation, the hE1o was
exchanged into 10 mM KH2PO4 (pH 7.5) containing 100 mM
NaCl, 0.5 mMThDP, and 1mMMgCl2. The hE2o, hE2o(1–173)
di-domain, and hE2o(144–386) core domain were exchanged
into 10mMKH2PO4 (pH7.5) containing 100mMNaCl. The hE3
was exchanged into 10 mM KH2PO4 (pH 7.5) containing 100
mM NaCl and 2 M FAD. All binary subcomplexes were pre-
pared by mixing an equal volume of each protein (160 M con-
centration stock concentration) to a final concentration of 80
M each. The samples were allowed to equilibrate for 1 h at
20 °C. The deuterium-labeling reaction was initiated by mixing
15 l of the protein samples with 285 l of labeling buffer (10
mMKH2PO4 (pH 7.5) containing 100mMNaCl and 99.9%D2O)
yielding a final concentration of 95% D2O. The samples were
incubated for an additional 20 s at 20 °C. For studies of the time
dependence of H/D exchange, incubation times of 1, 3, 10, 30,
90, and 270minwere used. After incubation for different times,
a 30-l aliquot from each labeling reactionmixture was rapidly
quenched into 36 l of ice-cold quench buffer (0.2 M KH2PO4
and 3 M guanidine hydrochloride (pH 2.1)) achieving a final pH
of 2.5 tominimize the rate of H/D back-exchange. The samples
were immediately frozen in liquid nitrogen and stored at
80 °C for no more than 2 weeks before analysis. Nondeuter-
ated samples were generated following the same procedure
except that protein samples were diluted into aqueous buffer
instead of labeling buffer andwere incubated for 5min followed
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by the quench process. All experiments were carried out in
triplicate. The frozen deuterated sample was quickly thawed
and loaded with an ice-cold syringe into a 20-l sample loop
inside the refrigeration system. The sample analysis was similar
to that reported by us previously (43, 53–55) using Bruker Dal-
tonics Data Analysis 4.0 for spectrum analysis and data treat-
ment. Peptides were identified from nondeuterated samples by
a customized programDxgest (57). H/D exchange data for each
individual peptide at various time points were processed using
HX-Express (58, 59). No back-exchange correction was needed
for the purpose of comparative analysis. The number of
exchangeable backbone amides (Dmax) of a peptide was calcu-
lated as the total number of residues excluding proline residues
and two fast exchangeable N-terminal residues (59, 60). The
percentage of deuterium incorporation (without back-ex-
change correction) of each peptide was calculated from the
equation D% D/(Dmax 1.0063 0.948) 100%, where
1.0063 is the atomic mass difference between deuterium and
hydrogen, and 0.948 represents the fractional D2O content of
the labeling reaction mixture. Butterfly and difference plots
were produced with Microsoft Excel.
Chemical cross-linking analysis of hE1o and hE2o
The hE1o (2 nmol, 66M subunits) in 50mMHEPES (pH 7.5)
containing 0.5 mM ThDP, 1.0 mM MgCl2, 0.15 M NaCl, and 1
mMbenzamidineHCl and the hE2o (1 nmol, 33M subunits) in
50 mM KH2PO4 (pH 7.2) containing 0.50 mM EDTA, 1.0 mM
DTT, 1.0 mM benzamidineHCl, and 0.40 M NH4Cl were mixed
at a 2:1 molar ratio of subunits in 30 l of 20 mM HEPES (pH
7.5) containing 300 mM NaCl. A 50-fold molar excess of
BuUrBu and 1000-fold molar excess of CDI over the concen-
tration of hE2o subunits, both dissolved in DMSO, were added,
and the cross-linking reactions were conducted at 15 °C for 30
min. To quench the reaction mixtures, 1 M TrisHCl (pH 8.0)
was added to a final concentration of 20mM. All reactions were
carried out in duplicate. Cross-linked hE1o–hE2o was identi-
fied by SDS-PAGE (5%). Next, cross-linked samples were pro-
cessed with tryptic in-solution digestion. An aliquot containing
1 nmol of the total protein was withdrawn from each reaction
mixture, and 5 l of 2% sodium deoxycholate and 2 l of 200
mM DTT were added, and then the samples were incubated at
60 °C for 30 min. Next, 2.5 l of 200 mM iodoacetamide was
added, and the sampleswere incubated for an additional 30min
at room temperature. The tryptic digestion was carried out at
1:35 protein/trypsinmolar ratio at 37 °C. After overnight diges-
tion, the reaction was terminated by addition of 1.5 l of 95%
formic acid. Cross-linked peptides were desalted on a SepPak
SPE column (Waters) and were dried in a SpeedVac (Savant).
Cross-linked peptides were analyzed by nano-LC-MS/MS
(Dionex Ultimate 3000 RLSC nanosystem interfaced with Q
Exactive HF (ThermoFisher Scientific, San Jose, CA)). Samples
were loaded onto a Magic C18AQ capillary trap unit (5 M
particle size, 200-Å pore size, and 100 m  2 cm) (Michrom
Bioresources, Inc.), and the trap unit was washed with mobile
phase consisting of 0.1% TFA for 5 min at a flow rate of 10
l/min. The trap was brought in-line with the analytical Magic
C18AQ column (3-m particle size, 200-Å pore size, and 75
m 50 cm), and cross-linked peptides were eluted using a
segmented linear gradient (4–15% A, 30 min; 15–25% B, 40
min; 25–50%B, 44min; 50–90%B, 11min; wheremobile phase
A consisted of 0.2% formic acid, and mobile phase B consisted
of 0.16% formic acid in 80% acetonitrile) at a flow rate of 300
nl/min. Mass spectrometric data were acquired using a data-
dependent acquisition procedure with a cyclic series of a full
scan with a resolution of 120,000, followed by MS/MS (higher-
energyC-trap dissociation; relative collision energy, 27%) of the
20 most intense ions and a dynamic exclusion duration of 20 s.
LC-MS/MS peak lists were generated using the ProteoWizard
software package (61) and searched against the SwissProt data-
base (using the MS-GF search engine). Search parameters
were as follows: fragment mass error, 20 ppm; parent mass
error, 5 ppm; fixed modification, carbamidomethylation on
cysteine; potential modifications during initial search, methio-
nine oxidation, and acetylation on protein N termini and up to
one missed tryptic cleavage. This search followed by extracted
ion chromatogram (XIC)-based quantitation showed that no
contaminant protein above 5% was present in the sample.
Cross-links were evaluated using software tool MeroX 1.5.1
(62) with the following parameters: precursor 5 ppm; fragment
20 ppmmass accuracy; CDI orBuUrBu set as cross-linker.With
both cross-linkers, only the Lys–Lys cross-linked peptides were
analyzed. The automatically identified cross-linked peptides
were manually analyzed, and the results with p  0.001 limit
were exported. The results were visualized on line using the
XVIS website (63).
Two-dimensional 1H-15N HSQCNMR
The NMR experiments were performed on a Varian INOVA
600 MHz spectrometer at 25 °C. For the HSQC NMR experi-
ment, a sample containing 200 M 15N-labeled hE1o was
exchanged into 50 mM K2HPO4 (pH 7.5) containing 100 mM
NaCl, 0.5 mM ThDP, 1.0 mM MgCl2, and 7% D2O for a lock
signal before the NMR spectrum was recorded.
Bioinformatics tools employed
Alignment of multiple sequences was carried out using the
Clustal Omega program (http://www.ebi.ac.uk/Tools/msa/
clustalo/)5 (64) with default settings. The secondary structure
of the E1o N-terminal region was calculated and predicted
with the JPred program (http://www.compbio.dundee.ac.uk/
jpred/)5 (65, 66). To predict the possible 3D structure of the E1o
N-terminal region, I-TASSER and SWISS-MODEL (http://
swissmodel.expasy.org/) were employed.
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